FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Current
FULGENT GENETICS, INC. (FLGT) had Debt Securities, Available-for-sale, Current of $230.73 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Current $230.73M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $252.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $285.88M.
- 2024-12-31: Debt Securities, Available-for-sale, Current $202.96M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $230.73M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $252.90M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $285.88M 10-Q · filed 2026-07-30 |
| 2024-12-31 | $202.96M 10-K · filed 2026-02-27 |
| 2020-12-31 | $211.94M 10-K · filed 2021-03-08 |
| 2020-09-30 | $21.90M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $18.53M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $18.03M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $16.30M 10-K · filed 2021-03-08 |
| 2019-09-30 | $11.60M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $17.82M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $24.14M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $24.30M 10-K · filed 2020-03-13 |
| 2018-09-30 | $24.11M 10-Q · filed 2018-11-09 |
| 2017-12-31 | $19.99M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |